Skip to main content

Advertisement

Table 2 Insulin versus hypoglycaemic drugs and placebo or diet

From: Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials

Studies Methodological quality: low, moderate, good (BlindingY/N) Participants (I/C) Treatment Follow-up (weeks) Inclusion criteria Primary outcome
Blicklé 2009 [48] Moderate (No) 102 (103/108) OHD (Met/S) + Insulin Glargine/Lifestyle management 36 weeks [7 %; 8 %]
[40y; 75y]
BMI: [24;35 kg/m2]
HbA1c
Russell Jones 2006 [49] Good (No) 581 (234/115/232) OHD (Met/S) + Insulin Glargine/Liraglutide placebo/Liraglutide 26 [7 %; 10 %]
BMI < 40 kg/m2
HbA1c
UKPDS 33 [13] Good (No) 3041 (911/1234/896) Insulin/Chlorpropamide or glibenclamide/diet 10 years 25-65 years
FBG 6,1–15 mmol/L
CV Morbimortality
UGDP [13, 5055] Good (Yes) 1027 (414/204/204/205) Insulin/Tolbutamide/Phenformin/placebo 10 years Diabete < 1 year Mortality
  1. I insulin, C control, OHD oral hypoglycaemic drugs, Met metformin, S sulphonylureas, TZD thazolidones, BMI body mass index, CV cardiovascular